TCV protects for over 4 years!

Single dose of TCV protects even the youngest children in Malawi

Typhoid continues to disproportionately impact children living in endemic areas, such as Malawi. TCV is a safe and cost-effective tool to address the substantial burden of disease and protect children living in high-risk countries.

Children recieving typhoid vaccine as part of the Zingwangwa Community Administration. Credit: MLW/Pauline Mlogeni

TCV offers protection for more than 4 years

TyVAC conducted a series of clinical trials to understand TCV performance in diverse populations. Previous data from a large randomized controlled trial led by Malawi-Liverpool-Wellcome Trust (MLW) showed a single dose of TCV is safe and more than 80% effective in protecting against typhoid for 18-24 months in Malawi. The study continued, and new data show TCV prevents blood culture-confirmed typhoid for more than 4 years among children aged 9 months-12 years.

Between February and September 2018, healthy children were randomly assigned in a 1:1 ratio to receive a single dose of TCV or meningococcal capsular group A conjugate (MenA) vaccine. The MLW team conducted passive surveillance at four sites where vaccinated participants would be tested for typhoid and other pathogens if they presented with a fever.

A total of 24 children in the TCV group and 110 children in the MenA group had a positive blood culture for Salmonella Typhi, the causative agent of typhoid. The overall vaccine efficacy of TCV – after more than 4 years – was 78%, with an estimated 1.3% decline in efficacy per year. Efficacies by age-group were approximately 71% in children aged 9 months to < 2 years, and 79-80% in children 2 to < 5 years, and 5 to 12 years.

Impact of the data

With increasing drug resistance, climate change, extreme weather events, and urbanization, the need to control typhoid is urgent. As the corresponding commentary highlights, the findings from this study reinforce what we already know – a single dose of TCV is safe, well-tolerated, and effective at protecting against typhoid. And, these critical longer-term data further support the cost-effectiveness of TCV. These results offer promise of saving lives and continued hope that decision-makers will prioritize TCV introduction to Take on Typhoid.

The full commentary written by International Vaccine Institute is available here.

Zingwangwa Community Typhoid Vaccine Administration. Credit: MLW/Pauline Mlogeni











Cover Photo: Children at Mitole Primary School children receive doses of typhoid vaccine. Credit: TyVAC/Madalitso Mvula.